Drug Information for Clindamycin Phosphate and Benzoyl Peroxide (Mylan Pharmaceuticals Inc.): ADVERSE REACTIONS

Ads

  • During clinical trials, the most frequently reported adverse event in the Clindamycin Phosphate and Benzoyl Peroxide Gel, 1%/5% treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the Clindamycin Phosphate and Benzoyl Peroxide Gel, 1%/5% and vehicle groups.

    Local Adverse Events - all causalities in >/= 1% of patients
    Clindamycin Phosphate and BenzoylPeroxide Gel, 1%/5%n = 420Vehiclen = 168
    Application Site Reaction13 (3%)1 (< 1%)
    Dry Skin50 (12%)10 (6%)
    Pruritis8 (2%)1 (< 1%)
    Peeling9 (2%)-
    Erythema6 (1%)1 (< 1%)
    Sunburn5 (1%)-

    The actual incidence of dry skin might have been greater were it not for the use of a moisturizer in these studies.

    Anaphylaxis, as well as allergic reactions leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Drug Information Provided by National Library of Medicine (NLM).
Ads

Ce site respecte les principes de la charte HONcode de HON

Ce site est destiné à être utilisé principalement comme un système de rappel pour les médecins qualifiés et d'autres professionnels médicaux. En utilisant ce site vous comprenez et acceptez que DiagnosisPro.com ne doit pas être employé comme un système de (Conditions d'utilisation). Ce site respecte les principes de la charte HONcode. Vérifiez ici.

© 2013 MedTech USA, Inc. (modifié le 05/16/13)